Get the Stockscreener App
6.79
1.16%
-0.08
After Hours:
6.80
0.010
+0.15%
Tempest Therapeutics Inc stock is traded at $6.79, with a volume of 33,556.
It is down -1.16% in the last 24 hours and up +9.16% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$6.87
Open:
$6.8
24h Volume:
33,556
Relative Volume:
0.57
Market Cap:
$24.38M
Revenue:
-
Net Income/Loss:
$-31.11M
P/E Ratio:
-4.4379
EPS:
-1.53
Net Cash Flow:
$-28.18M
1W Performance:
+1.80%
1M Performance:
+9.16%
6M Performance:
-45.96%
1Y Performance:
-84.08%
1-Day Range:
$6.50
$6.9757
1-Week Range:
$6.2506
$6.9757
52-Week Range:
$5.3495
$47.45
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
6.79 | 24.38M | 0 | -31.11M | -28.18M | -1.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan
Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com
Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times
Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq
Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire
Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan
Tempest Therapeutics regains Nasdaq compliance - Investing.com
Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX
Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE
Tempest Therapeutics - The Pharma Letter
Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria
Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times
Tempest to explore alternatives to advance promising pipeline - The Pharma Letter
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN
Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive
HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com
Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance
Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News
Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa
Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks
Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com
Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com
Tempest Therapeutics evaluates strategic options amid advancements - Investing.com
Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire
Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com Australia
Tempest Therapeutics announces 1-for-13 reverse stock split By Investing.com - Investing.com Canada
Tempest Therapeutics Announced 1-For-13 Reverse Stock Split - marketscreener.com
Top Analysts Slash Price Targets for Meta Platforms Stock (META) on Macro and Tariff Concerns - The Globe and Mail
TPST stock touches 52-week low at $0.69 amid market challenges - Investing.com Canada
TPST stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):